Therapy of Acute Myeloid Leukemia

Rai K.R. , Holland J.F. , Glidewell O.J. . Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981; 58: 1203–1212.

Yates J. , Glidewell O. , Wiernik P. . Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60: 454–462.

Preisler H.D. , Anderson K. , Rai K. . The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimum follow-up time of 6 years. Br J Haematol. 1989; 71: 189–194.

Bandini G. , Zuffa E. , Rosti G. . Long-term outcome of adults with acute myelogenous leukemia: results of a prospective randomized study of chemotherapy with a minimal follow-up of 7 years. Br J Haematol. 1991; 77: 486–490.

Rowe J.M. , Andersen J. , Cassileth P.A. . Clinical trials of adults with acute myelogenous leukemia: experience of the Eastern Cooperative Oncology Group. In: Hid-demann W. , Buchner T. , Wormann B. , eds. Acute Leukemia IV: Experimental Approaches and Novel Therapies. Berlin: Springer-Verlag; 1994: 542.

Bennett J.M. , Young M.L. , Andersen J.W. . Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997; 80(11 suppl): 2205–2209.

Bennett J.M. , Catovsky D. , Daniel M.T. . Proposed revised criteria for the classification of acute myeloid leukemia: a report from the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620–625.

Harris N.L. , Jaffe E.S. , Diebold J. . World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835–3849.

Keating M.J. , Smith T.L. , Kantarjian H. . Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988; 2: 403–412.

Van Putten W.L.J. , Löwenberg B. . Prognostic factors in adult AML. Blood. 1997; 90: 65a. Abstract.

Fenaux P. , Preudhomme C. , Lai J.L. . Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol. 1989; 73: 61–67.

Schiffer C.A. , Lee E.J. , Tomiyasu T. . Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989; 73: 263–270.

Dastugue N. , Payen C. , Lafage-Pochitaloff M. . Prognostic significance of karyotype in de novo adult acute myeloid leukemia: the BGMT group. Leukemia. 1995; 9: 1491–1498.

van den Heuvel-Eibrink M.M. , van der Holt B. , te Boekhorst P.A. . MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol. 1997; 99: 76–83.

Leith C.P. , Kopecky K.J. , Godwin J. . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323–3329.

Stasi R. , Venditti A. , Del Poeta G. . Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Cancer. 1996; 77: 2476–2488.

Grimwade D. , Walker H. , Oliver F. . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood. 1998; 92: 2322–2333.

Mrozek K. , Heinonen K. , de la Chapelle A. . Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997; 24: 17–31. Review.

Schoch C. , Haase D. , Haferlach T. . Fifty-one patients with acute myeloid leukemia and translocation t(8;21) (q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996; 10: 1288–1295.

Schoch C. , Haase D. , Fonatsch C. . The significance of trisomy 8 in de novo acute myeloid leukemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol. 1997; 99: 605–611.

Yamamoto K. , Seto M. , Iida S. . A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities. Blood. 1994; 83: 2912–2921.

Mrozek K. , Heinonen K. , Lawrence D. . Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group study. Blood. 1997; 90: 4532–4538.

Archimbaud E. , Charrin C. , Magaud J.P. . Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Leukemia. 1998; 12: 25–33.

Baer M.R. , Stewart C.C. , Lawrence D. . Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997; 90: 1643–1648.

Baudard M. , Beauchamp-Nicoud A. , Delmer A. . Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999; 13: 1481–1490.

Freireich E.J. . Arabinosyl cytosine: a 20-year update. J Clin Oncol. 1987; 5: 523–524.

Coltman CA Jr , Freireich E.J. , Pendle-ton O. . Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials. Med Pediatr Oncol. 1982; 10: 173–183.

Weil M. , Glidewell O.J. , Jacquillat C. . Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973; 33: 921–928.

Preisler H. , Davis R.B. , Kirshner J. . Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood. 1987; 69: 1441–1449.

Dillman RO Davis R.B. , Green M.R. . A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991; 78: 2520–2526.

Rowe J.M. , Tallman M.S. . Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood. 1997; 90: 2121–2126.

Speth P.A. , Minderman H. , Haanen C. . Idarubicin vs daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol. 1989; 16: 2–9. Review.

Curtis J.E. , Minden M.D. , Minkin S. . Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors. Leukemia. 1995; 9: 396–404.

Ross D. , Tang Y. , Comblatt B. . Idarubicin (IDA) in less vulnerable to transportmediated multidrug resistance (MDR) than its metabolite idarubicinol (IDA-ol) or daunorubicin. Blood. 1993; 10: 1015.

Roovers D.J. , van Vliet M. , Bloem A.C. . Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res. 1999; 23: 539–548.

Berman E. , Heller G. , Santorsa J. . Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991; 77: 1666–1674.

Wiernik P.H. , Banks P.L. , Case DC Jr . Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313–319.

Vogler W.R. , Velez-Garcia E. , Weiner R.S. . A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992; 10: 1103–1111.

Mandelli F. , Petti M.C. , Ardia A. . A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia: a multicentric study from the Italian Cooperative Group GIMEMA. Eur J Cancer. 1991; 27: 750–755.

The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol. 1998; 103: 100–109.

Grant S. , Arlin Z. , Gewirtz D. . Effect of pharmacologically relevant concentrations of mitoxantrone or the in vitro growth of leukemic blast progenitors. Leukemia. 1991; 5: 336–339.

Arlin Z. , Case DC Jr , Moore J. . Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL) Lederle Cooperative Group. Leukemia. 1990; 4: 177–183.

Wahlin A. , Hornsten P. , Hedenus M. . Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 1991; 28: 480–483.

Pavlovsky S. , Gonzalez Llaven J. , Garcia Martinez M.A. . A randomized study of mitoxantrone plus cytarabine versus daunorubicin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol. 1994; 69: 11–15.

Hansen O.P. , Pedersen-Bjergaard J. , Ellegaard J. . Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia. 1991; 5: 510–516.

Berman E. , Arlin Z.A. , Gaynor J. . Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia. 1989; 3: 115–121.

Buchner T. , Hiddemann W. , Wormann B. . Daunorubicin 60 instead of 30 mg/sqm improves response and survival in elderly patients with AML. Blood. 1997; 90: 2596. Abstract.

Feldman E.J. , Seiter K. , Damon L. . A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997; 11: 485–489.

Rowe J.M. , Neuberg D. , Friedenberg W. . A Phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 years) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993). Blood. 1998; 92: 1284.

Löwenberg B. , Suciu S. , Archimbaud E. . Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. J Clin Oncol. 1998; 16: 872–881.

Burnett A.K. , Goldstone A.H. , Milligan D.W. . Daunorubicin versus mitoxantrone as induction for AML in younger patients given intensive chemotherapy. Preliminary results of MRC AML-12 trial. Br J Haematol. 1999; 105(suppl 1): 154.

Zittoun R. , Suciu S. , DeWitte T. . Comparison of three intercalating agents in induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic transplantation: preliminary results of the EORTC-GIMEMA AML-10 randomized trial. Blood. 1999; 94: 2923.

Schiller G. , Gajewski J. , Nimer S. . A randomized study of intermediate- versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haematol. 1992; 81: 170–177.

Bishop J.F. , Matthews J.P. , Young G.A. . A randomized trial of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87: 1710–1717.

Weick J.K. , Kopecky K.J. , Appelbaum F.R. . A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996; 88: 2841–2851.

Bishop J.F. , Lowenthal R.M. , Joshua D. . Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990; 75: 27–32.

Bishop J.F. , Matthews J.P. , Young G.A. . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma. 1998; 28: 315–327. Review.

Hann I.M. , Stevens R.F. , Goldstone A.H. . Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997; 89: 2311–2318.

Mitus A.J. , Miller K.B. , Schenkien D.P. . Improved survival for patients with acute myelogenous leukemia. J Clin Oncol. 1995; 13: 560–569.

Cassileth P.A. , Lee S.J. , Miller K.B. . Feasibility study of adding high-dose cytarabine (HDAC) in induction (IND) and in consolidation (CONS) before autologous stem cell transplant (ASCT) in adult acute myeloid leukemia (AML). Blood. 1998; 92: 4559. Abstract.

Petersdorf S. , Rankin C. , Terebolo H. . A phase II study of standard dose daunomycin and cytosine arabinoside (Ara-C) with high-dose Ara-C induction therapy followed by sequential high-dose Ara-C consolidation for adults with previously untreated acute myelogenous leukemia: a Southwest Oncology Group study (SWOG 9500). Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 55. Abstract.

Buchner T. , Hiddemann W. , Wormann B. . Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999; 93: 4116–4124.

Buchner T. , Hiddemann W. , Koenigs-mann M. . Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood. 1991; 78: 1190–1197.

Rowe J.M. , Andersen J. , Mazza J.J. . A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457–462.

Dombret H. , Chastang C. , Fenaux P. . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patents after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995; 332: 1678–1683.

Heil G. , Hoelzer D. , Sanz M.A. . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia: the International Acute Myeloid Leukemia Study Group. Blood. 1997; 90: 4710–4718.

Godwin J.E. , Kopecky K.J. , Head D.R. . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 1998; 91: 3607–3615.

Stone R.M. , Berg D.T. , George S.L. . Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995; 332: 1671–1677.

Zittoun R. , Suciu S. , Mandelli F. . Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996; 14: 2150–2159.

Löwenberg B. , Suciu S. , Archimbaud E. . Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer and the Dutch Belgium Hemato-Oncology Cooperative Group. Blood. 1997; 90: 2952–2961.

Link H. , Wandt H. , Schonrock-Nabulski P. . G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: a placebo controlled trial. Blood. 1996; 88: 2654.

Goldstone A.H. , Burnett A.K. , Milligan D.W. . Lack of benefit of G-CSF on complete remission and possible increased relapsed risk in AML: an MRC study of 800 patients. Blood. 1997; 90: 2595.

Witz F. , Harousseau J.L. , Sadoun A. . GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematol Blood Transfus. 1997; 40: 852–856.

Schiffer C.A. . Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996; 88: 3675–3685.

Cassileth P.A. , Harrington D.P. , Hines J.D. . Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol. 1988; 6: 583–587.

Robles C. , Kim K.M. , Oken M.M. . Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 2000; 14: 1349–1353.

Buchner T. , Hiddemann W. , Wormann B. . Late events in AML: data from long-term observation of patients in two trials starting in 1981 and 1985. Blood. 1997; 90: 2247.

Rees J.K.H. , Gray R.G. , Wheatley K. . Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost: principal report of the Medical Research Council's AML9 study. Br J Haematol. 1996; 94: 89–98.

Mayer R.J. , Davis R.B. , Schiffer C.A. . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896–903.

Cassileth P.A. , Lynch E. , Hines J.D. . Varying intensity of post remission therapy in acute myeloid leukemia. Blood. 1992; 79: 1924–1930.

Elonen E. , Almqvist A. , Hanninen A. . Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia. 1998; 12: 1041–1048.

Zittoun R.A. , Mandelli F. , Willemze R. . Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematol-giche Maligne dell-Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217–223.

Cassileth P. , Harrington D. , Paietta E. . Comparison of autologous bone marrow transplantation (AUTOBMT) with highdose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG Intergroup study. Proc Annu Meet Am Soc Clin Oncol. 1997; 16: 311.

Harousseau J.L. , Cahn J.Y. , Pignon B. . Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia: the Groupe Ouest Est Leuccemies Aigues Myeloblastiques (GOE-LAM). Blood. 1997; 90: 2978–2986.

Burnett A.K. , Goldstone A.H. , Stevens R.M. . Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998; 351: 700–708.

Soiffer R.J. , Fairclough D. , Robertson M. . CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997; 89: 3039–3047.

Papadopoulos E.B. , Carabasi M.H. , Castro-Malaspina H. . T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998; 91: 1083–1090.

Cahn J.Y. , Labopin M. , Schattenberg A. . Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia. 1997; 11: 416–419.

Byrd J.C. , Dodge R.K. , Carroll A. . Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999; 17: 3767–3775.

Huang M.E. , Ye Y.C. , Chen S.R. . Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72: 567–572.

Castaigne S. , Chomienne C. , Daniel M.T. . All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990; 76: 1704–1709.

Warrell RP Jr , Frankel S.R. , Miller WH Jr . Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991; 324: 1385–1393.

Fenaux P. , Castaigne S. , Dombret H. . All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood. 1992; 80: 2176–2181.

Chen Z.X. , Xue Y.Q. , Zhang R. . A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991; 78: 1413–1419.

Kanamaru A. , Takemoto Y. , Tanimoto M. . All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995; 85: 1202–1206.

Ohno R. , Yoshida H. , Fukutani H. . Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. Leukemia. 1993; 7: 1722–1727.

Avvisati G. , Lo Coco F. , Diverio D. . AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996; 88: 1390–1398.

Mandelli F. , Diverio D. , Avvisati G. . Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997; 90: 1014–1021.

Sanz M.A. , Martin G. , Rayon C. . A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999; 94: 3015–3021.

Fenaux P. , Le Deley M.C. , Castaigne S. . Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993; 82: 3241–3249.

Tallman M.S. , Andersen J.W. , Schiffer C.A. . All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997; 337: 1021–1028.

De Botton S. , Dombret H. , Sanz M. . Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998; 92: 2712–2718.

Tallman M.S. , Andersen J.W. , Schiffer C.A. . Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000; 95: 90–95.

Fenaux P. , Chastang C. , Chevret S. . A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999; 94: 1192–1200.

Burnett A.K. , Grimwade D. , Solomon E. . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood. 1999; 93: 4131–4143.

Sanz M.A. , Coco F.L. , Martin G. . Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study by the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96: 1247–1253.

Kahn S.B. , Begg C.B. , Mazza J.J. . Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1984; 2: 865–870.

Tucker J. , Thomas A.E. , Gregory W.M. . Acute myeloid leukemia in elderly adults. Hematol Oncol. 1990; 8: 13–21.

Taylor P.R. , Reid M.M. , Stark A.N. . De novo acute myeloid leukaemia in patients over 55 years old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia. 1995; 9: 231–237.

Leith C.P. , Kopecky K.J. , Chen I.M. . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999; 94: 1086–1099.

Löwenberg B. , Zittoun R. , Kerkhofs H. . On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268–1274.

Tilly H. , Castaigne S. , Bordessoule D. . Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer. 1985; 55: 1633–1636.

Leyden M. , Manoharan A. , Boyd A. . Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction. Br J Haematol. 1984; 57: 301–307.

Cheson B.D. , Jasperse D.M. , Simon R. . A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986; 4: 1857–1864. Review.

Rossi Ferini P. , Bernabei P.A. , Leoni F. . Low-dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia in the elderly. New Trends Ther Leuk Lymph. 1986; 1: 79–85.

Powell B.L. , Capizzi R.L. , Muss H.B. . Low-dose ara-C therapy for acute myeloge-nous leukemia in elderly patients. Leukemia. 1989; 3: 23–28.

Detourmignies L. , Wattel E. , Lai J.L. . Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases. Ann Hematol. 1993; 66: 235–240.

Bow E.J. , Sutherland J.A. , Kilpatrick M.G. . Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol. 1996; 14: 1345–1352.

Tallman M.S. , Rowlings P.A. , Milone G. . Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000; 96: 1254–1258.

Gale R.P. , Horowitz M.M. , Weiner R.S. . Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995; 16: 203–208.

Ferrant A. , Doyen C. , Delannoy A. . Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant. 1995; 15: 685–690.

Slovak M.L. , Kopecky K.J. , Cassileth P.A. . Karyotype analysis predicts outcome of pre- and postremission therapy in adult acute myeloid leukemia (AML): a SWOG/ECOG Intergroup Study. Blood. 1998; 92: 2795.